← back to search

Sandra J. Horning

Acentech (United States) · US
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, and Lung Cancer Treatments and Mutations.
h-index
75
citations
32,452
works
307
NIH funding
primary concept
email

Recent publications

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis
Cancer 2017cited by 59position: middledoi
Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era
British Journal of Haematology 2015cited by 75position: middledoi
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant
Leukemia & lymphoma/Leukemia and lymphoma 2013cited by 141position: lastdoi
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and <scp>S</scp>tanford <scp>V</scp> in older <scp>H</scp>odgkin lymphoma patients: a comprehensive analysis from the <scp>N</scp>orth <scp>A</scp>merican intergroup trial <scp>E</scp>2496
British Journal of Haematology 2013cited by 140position: lastdoi
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
Blood 2013cited by 139position: middledoi
Developing Standards for Breakthrough Therapy Designation in Oncology
Clinical Cancer Research 2013cited by 29position: firstdoi
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
Blood 2012cited by 208position: middledoi
Long‐term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma
British Journal of Haematology 2012cited by 26position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Randy D. Gascoyne · BC Cancer Agency5 papers (2012–2017)Ranjana H. Advani · Stanford Medicine5 papers (2012–2017)Brad S. Kahl · New York University5 papers (2012–2017)Fangxin Hong · Pfizer (United States)5 papers (2012–2017)Nancy L. Bartlett · City of Hope5 papers (2012–2017)Leo I. Gordon · Northwestern University5 papers (2012–2017)Richard I. Fisher · University of Arizona4 papers (2012–2015)Richard T. Hoppe · Stanford Medicine3 papers (2012–2015)Bruce D. Cheson · Center for Cancer and Blood Disorders3 papers (2013–2015)Patrick J. Stiff · Dana-Farber Cancer Institute3 papers (2013–2015)Joseph M. Connors · Spinal Cord Injury BC3 papers (2012–2017)Jonathan W. Friedberg · University of Rochester2 papers (2015–2017)Andrew M. Evens · Rutgers, The State University of New Jersey2 papers (2013–2017)Henry Wagner · Pennsylvania State University2 papers (2013–2015)King Tan · Westmead Hospital2 papers (2012–2013)Thomas P. Miller · Queen Elizabeth University Hospital2 papers (2013–2013)Hailun Li · Hospital for Sick Children2 papers (2013–2015)Charles L. Sawyers · Molecular Oncology (United States)1 papers (2013–2013)Jennifer A. Kanakry · Cancer Institute (WIA)1 papers (2013–2013)Daniel A. Haber · Rambam Health Care Campus1 papers (2013–2013)